$1M funding for AI drug discovery for rare diseases and more digital health fundings

0
21



Indian AI drug discovery agency will get $1M to give attention to uncommon ailments

Peptris Applied sciences from Bangalore, India has acquired $1 million in pre-seed funding in a spherical led by Speciale Make investments.

In a press release, the AI-driven drug discovery firm mentioned it should use its contemporary funds to increase its analysis scope to cowl uncommon ailments, including to its current work in most cancers and irritation. 


Cipla raises stake in digital pharma options supplier GoApptiv

Indian pharmaceutical big Cipla has elevated its stake in GoApptiv by Rs 420 million ($5 million) to 22.99%. 

It has additional invested within the firm, which develops end-to-end digital options for pharmaceutical corporations, as a part of its efforts to penetrate underserved communities throughout India and helimprove entry to medicines. 


Canadian insurtech Lydia AI targets South Korea

Lydia AI, a Canada-based medical insurance AI firm, has just lately signed know-how integration partnerships in South Korea.

It has formalised its ongoing collaboration with Hecto Information; they’re piloting a wise knowledge ecosystem inside insurer Metlife Korea’s 360Health software. 

The Canadian insurtech has additionally entered into a brand new partnership with Tobecon to combine its predictive AI functionality into insurance coverage software program.


 Ubie to launch Android model of AI symptom checker app within the US

Japanese startup Ubie is making ready to launch the Android model of its AI-enabled symptom checker app in america. 

The cell symptom checker, whose AI functionality was just lately recognised at Google Play’s Better of 2023 Awards, helps customers in figuring out their signs and connects them with the fitting healthcare supplier. It’s now used over 100 million occasions since 2020; since launching within the US final 12 months, it has greater than two million makes use of up to now.

LEAVE A REPLY

Please enter your comment!
Please enter your name here